Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

$238.54M

FY 2025 · Annual

Investing Cash Flow

-$105.28M

FY 2025 · Annual

Financing Cash Flow

-$3.25M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(265.07M)(92.82M)(55.19M)(56.42M)105.9M
Depreciation & Amortization8.6M7.02M4.26M3.62M5.64M
Deferred Income Tax003.21M(7.57M)(11.52M)
Stock-Based Compensation62.06M39.73M25.37M21.39M18.48M
Change in Working Capital(39.55M)42.35M(8.34M)20.36M120.47M
Accounts Receivables1.8M(2.72M)(689K)(966K)(27.1M)
Inventory00000
Accounts Payables(3.53M)(1.61M)6K750K326K
Other Working Capital(37.82M)46.68M(7.66M)20.57M147.24M
Other Non-Cash Items26.1M(183.28M)3.7M7.09M(423K)
Operating Cash Flow(207.86M)(186.99M)(27M)(11.54M)238.54M
Capital Expenditures(3.41M)(572K)(2.49M)(332K)(42K)
Acquisitions (Net)00000
Purchases of Investments(158.31M)(103.15M)(134.53M)(143.04M)(248.22M)
Sales of Investments286.2M158.02M102.81M155.65M142.98M
Other Investing Activities6K1.1B1.51M00
Investing Cash Flow124.49M1.15B(32.7M)12.28M(105.28M)
Debt Repayment(10.73M)(631.6M)000
Common Stock Issued108.18M0099K786K
Common Stock Repurchased(9.06M)(132.28M)(199.55M)(3.1M)(4.03M)
Dividends Paid00000
Other Financing Activities3.47M5.08M618K508K0
Financing Cash Flow91.86M(758.81M)(198.93M)(2.5M)(3.25M)
Effect of Forex Changes00000
Net Change in Cash8.5M208.21M(258.63M)(1.75M)130.01M
Free Cash Flow(211.26M)(187.56M)(29.49M)(11.87M)238.5M

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income$105.9M
+ D&A$5.6M
+ Stock-Based Comp$18.5M
- Deferred Tax-$11.5M
+ Working Capital$120.5M
- Other Non-Cash-$423.0K
= Operating Cash Flow$238.5M
- Capex-$42.0K
= Free Cash Flow$238.5M

Analysis

FY2025 free cash flow is $238.5M. FCF conversion is 225.2% of net income. Operating cash flow was $238.5M, with capex of -$42.0K. The largest bridge item is Working Capital at $120.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13D/ASC 13D/A filingSep 25, 2026
4Statement of changes in beneficial ownershipSep 24, 2026
S-8 POSS-8 POS filingSep 24, 2026
4Statement of changes in beneficial ownershipSep 24, 2026
4Statement of changes in beneficial ownershipSep 24, 2026

Does TBPH generate free cash flow?

Theravance Biopharma, Inc. (TBPH) generated $238.50M of free cash flow in fiscal 2025.

How much operating cash flow does TBPH produce?

Operating cash flow was $238.54M, before capital expenditures of $42,000.00.